ArticleMolecular biology reports2026
Kaempferol attenuates LPS-induced inflammatory responses in H9c2 cells through involvement of the IL-6/JAK2/STAT3 pathway.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundKaempferol (Kae), a flavonoid compound, has shown considerable potential in preventing and treating cardiovascular diseases and ameliorating myocardial damage. However, its underlying mechanisms remain complex and require further elucidation. This study investigated the protective effects of Kae pretreatment against lipopolysaccharide (LPS)-induced inflammatory responses in H9c2 cardiomyocytes through the interleukin-6 (IL-6)/Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) signaling pathway, aiming to establish a theoretical foundation for Kae development and clinical application.
methodsInitially, potential targets were identified through network pharmacology and molecular docking. The protective efficacy of Kae against CS was then preliminarily validated in vivo via histopathological analysis (hematoxylin and eosin staining). Finally, an LPS-induced CS model was constructed in H9c2 cardiomyocytes to elucidate the underlying mechanisms in vitro.
resultsNetwork pharmacology analysis indicated that Kae may exert anti-CS effects via modulation of the IL-6/JAK2/STAT3 signaling pathway. In vivo experiments demonstrated that Kae significantly ameliorated histopathological changes, including disorganized myocardial fibers and inflammatory cell infiltration. Compared with the model group, serum levels of tumor necrosis factor alpha (TNF-α), IL-6, and interleukin-1β (IL-1β) were significantly decreased, along with reduced mRNA expression of these cytokines in cardiac tissue. In vitro, LPS stimulation significantly elevated the levels of TNF-α, IL-6, and IL-1β, and increased phosphorylated Janus kinase 2 (p-JAK2) and phosphorylated signal transducer and activator of transcription 3 (p-STAT3) expression compared with the control group (P < 0.01). Kae pretreatment significantly reduced these inflammatory mediators and downregulated p-JAK2 and p-STAT3 expression compared with the LPS group (P < 0.01). Additionally, Kae pretreatment increased superoxide dismutase activity while decreasing malondialdehyde content and nitric oxide production (P < 0.05).
conclusionKae pretreatment demonstrated a protective effect against the LPS-induced inflammatory response in H9c2 cells. This protective effect potentially involves regulating the IL-6/JAK2/STAT3 signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.